Euro
USD
British Pound
NULL
Product Description
LYVE1 polyclonal Antibody | AP0017 | Bioworld
Host: Rabbit
Reactivity: Human,Mouse,Rat
Application: WB
Application Range: WB: 1:500~1:1000
Background: Recently a number of interesting molecules have been identified that may be exploited as markers for lymphatic endothelium, including the hyaluronan receptor LYVE1, PALE, VEGFR3, podoplanin. LYVE1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels.
Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity: LYVE-1 polyclonal Antibody detects endogenous levels of LYVE-1 protein.
Molecular Weight: ~ 36 kDa
Note: For research use only, not for use in diagnostic procedure.
Alternative Names: Cell surface retention sequence-binding protein 1; CRSBP 1; CRSBP-1; CRSBP1; extracellular link domain containing 1; extracellular link domain-containing 1; Extracellular link domain-containing protein 1; HAR; hyaluronic acid receptor; Lymphatic endothelium specific hyaluronan receptor; lymphatic vessel endothelial hyaluronan receptor 1; Lymphatic vessel endothelial hyaluronic acid receptor 1; LYVE 1; LYVE-1; LYVE1; LYVE1; XLKD1;
Immunogen: Synthetic peptide, corresponding to amino acids 60-110 of Human LYVE-1.
Conjugate: Unconjugated
Modification: Unmodification
Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .
Pathway: Mitochondrial Control of Apoptosis,Epigenetic Writers and Erasers of Histone H3,Epigenetic Writers and Erasers of Histones H2A H2B and H4,
